News and Press Releases
CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT
CluePoints is a cloud-based software platform for Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials, designed to enable safer and more efficient processes and improving data integrity...
Category: Biotechnology, Clinical Trials
Posted: June 12, 2024
SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases
12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024
Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage
11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024
CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange
11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...
Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024
Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands
Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia
After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain
The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Eisai Named on TIME100 Most Influential Companies 2024 List
3 June 2024 -- Tokyo, Japan -- Eisai Co announced today that TIME has selected Eisai as one of the TIME100 Most Influential Companies of 2024. TIME reveals the TIME100...
Category: Biotechnology, Other
Posted: June 3, 2024
DARZALEX (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
88% of transplant-eligible patients achieved a complete response or better, and 47% of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in the phase 3...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Lykos Therapeutics Appoints Finance Veteran Scott Giacobello to the Board of Directors
30 May 2024 -- California, US -- Lykos Therapeutics, a company dedicated to transforming mental healthcare, announced the appointment of finance veteran Scott Giacobello to the company's Board of Directors, effective immediately. A...
Category: Biotechnology, Clinical Trials, Other
Posted: May 30, 2024
Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1-ALS is a devastating, uniformly fatal and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe QALSODY is Biogen’s third rare disease therapy to be...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 30, 2024
Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
23 May 2024 -- Tokyo, Japan -- Eisai Co announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American...
Category: Clinical Trials, Drug Discovery
Posted: May 23, 2024
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its...
Category: Drug Discovery, Pharmaceutical
Posted: May 22, 2024
Mission Therapeutics commences landmark trial of MTX325, a potential disease-modifying treatment for Parkinson’s Disease
Builds on preclinical proof-of-concept that MTX325 protects dopamine-producing brain cells by enhancing mitophagy – the process cells use to remove dysfunctional mitochondria 21 March 2024 -- Cambridge, UK -- Mission...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: May 21, 2024
Moneta (Building 280), Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
National Minority Quality Forum And Biogen Release a Report Highlighting a Model to Improve Clinical Trial Diversity
Partnership works to improve outcomes for Black and Hispanic women living with lupus 20 May 2024 -- Washington, DC -- The National Minority Quality Forum and Biogen released a report, Improving Diversity in Clinical Trials,...
Category: Clinical Trials, Other
Posted: May 20, 2024
1201 15th Street, NW, Suite 340 Washington, DC, 20005
